Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
Multiple menin inhibitor drugs are advancing clinical development, potentially transforming treatment options for certain types of acute leukemia.
This review synthesizes the rapidly evolving field of menin inhibitors for AML treatment, covering four clinical-stage drugs and their combination strategies. It provides a timely update on a therapeutic class that is transforming treatment of KMT2A-rearranged and NPM1-mutated leukemias.
What the study was
- Study design
- Comprehensive review
- Population
- Patients with KMT2A-rearranged and NPM1-mutated AML
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Journal of Haematology
Why it surfaced
Menin inhibitors represent a new therapeutic class with breakthrough designations for AML. This is a comprehensive, up-to-date review covering 4 agents in clinical development. Highly relevant to hematologic malignancy watchlist and actionable for the pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.